Hematopoietic Growth Factor Inducible Neurokinin-1 Gene and Uses Thereof
AssigneeUniversity of Medicine and Dentistry of New Jersey
InventorPranela Rameshwar
Life of this patent
Estimating the term…
Abstract
The present invention discloses the cloning of a new cDNA, HGFIN, from stimulated bone marrow stromal cells that was retrieved with a probe specific for the neurokinin-1 (NK-1) receptor. The novel gene, HGFIN, encodes a protein receptor that is involved in the regulation of hematopoietic proliferation and differentiation. HGFIN is implicated in the treatment of hyperproliferative disorders, particularly bone and breast cancer, because it acts to suppress the proliferating cells.
Claims10
A method for inhibiting the growth of a breast cancer cell comprising contacting a breast cancer cell with an effective amount of Hematopoietic Growth Factor Inducible Neurokinin-1 (HGFIN) thereby inhibiting the growth of the cancer cell.
A method of treating breast cancer, comprising administering to a patient in need of treatment an effective dose of HGFIN with an amino acid sequence of SEQ ID NO:2 in a pharmaceutically acceptable carrier.
A method for reversing chemotherapeutic drug resistance in cancer cells exhibiting chemotherapeutic drug resistance comprising contacting cancer cells with an agent that inhibits the activity of HGFIN in combination with a chemotherapeutic drug to which said cancer cells have become resistant wherein contacting said cancer cells with the agent that inhibits HGFIN and the chemotherapeutic drug results in inhibition of cancer cell growth.
Dependencies are inferred from the claim text.